PSMA Ligand Linker Design to Reduce Renal and Salivary Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PSMA ligands for prostate cancer imaging and therapy suffer from high renal and salivary gland uptake, leading to significant side effects and dose limitations, particularly during alpha therapy with 225Ac.
Innovation Solution
Development of new PSMA binding ligands comprising a PSMA binding motif Q and a chelator residue A linked via a linker LAQ, which includes neutral amino acids, to improve tissue specificity and reduce non-target tissue accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current PSMA ligands are used for prostate cancer imaging and therapy, then PSMA target binding is achieved, but high renal and salivary gland uptake occurs leading to significant side effects and dose limitations
Solution Approach 1:
The patent modifies specific local properties of the PSMA ligand by introducing fluorine atoms at particular positions (e.g., 8-fluoro, 6-fluoro substitutions on the bicyclic ring system) and adjusting the linker composition (using neutral amino acids like glycine, alanine, or beta-alanine). These localized chemical modifications selectively reduce uptake in renal and salivary gland tissues while preserving high-affinity binding to PSMA-expressing prostate cancer cells, thereby reducing side effects without compromising therapeutic efficacy
Solution Approach 2:
The patent systematically varies key parameters of the PSMA ligand structure including: (1) fluorine substitution patterns on the bicyclic ring system, (2) amino acid composition and length of the linker (LAQ) between the PSMA binding motif and chelator, and (3) chelator type (DOTA, NOTA, NODAGA). These parameter changes optimize the balance between target binding affinity and non-specific tissue uptake, reducing renal and salivary gland accumulation while maintaining reliable therapeutic action against prostate cancer
2Reliability
If PSMA ligands are administered at higher doses to enhance therapeutic efficacy, then treatment effectiveness improves, but non-target tissue accumulation increases causing dose limitations
Solution Approach 1:
By introducing fluorine atoms at specific positions on the bicyclic ring system (such as 8-fluoro or 6-fluoro substitutions) and optimizing the linker composition with neutral amino acids, the patent creates localized modifications that selectively reduce affinity for renal and salivary gland tissues. This allows higher doses to be administered because the modified ligand structure inherently resists accumulation in these non-target organs, thereby enabling dose escalation to achieve therapeutic efficacy without being constrained by toxicity thresholds
Solution Approach 2:
The patent optimizes multiple structural parameters simultaneously: fluorine substitution patterns, linker amino acid sequence and length, and chelator selection. These parameter optimizations collectively reduce the ligand's propensity to accumulate in non-target tissues, thereby expanding the safe dosing range and allowing higher administered doses that achieve effective therapeutic concentrations at the tumor site without exceeding safety limits in healthy organs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new PSMA binding ligands demonstrate reduced uptake in non-target tissues, minimizing side effects and enhancing the therapeutic efficacy for prostate cancer treatment.
Implementation Method 1
Radioactive molecules that selectively bind to specific tumor cell surface proteins provide an attractive route for imaging and treating tumors under non-invasive conditions
Implementation Method 2
A variety of radionuclides are known to be useful for radio-imaging or cancer radiotherapy, including 111In, 90Y, 68Ga, 177Lu, 99mTc, 123I and 131I
Data Source
AI summary
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof as well as to the use of said PSMA binding ligand, the PSMA binding ligand comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQ comprising at least one, optionally N-alkylated, neutral amino acid Xi.